Biologic outcomes in U.S. Hispanic and Black patients with severe asthma

J Allergy Clin Immunol Pract. 2024 Oct;12(10):2844-2846.e1. doi: 10.1016/j.jaip.2024.06.020. Epub 2024 Jun 18.

Authors

Jennifer Trevor¹, Wendy C Moore², Njira Lugogo³, Dennis K Ledford⁴, Alexander Mackie⁵, Donna Carstens⁵, Nereida A Parada⁶, Christopher S Ambrose⁷

Affiliations

¹ University of Alabama at Birmingham, Birmingham, Ala.
² Wake Forest School of Medicine, Winston-Salem, NC.
³ University of Michigan, Ann Arbor, Mich.
⁴ University of South Florida, Tampa, Fla.
⁵ BioPharmaceuticals Medical, AstraZeneca, Wilmington, Del.
⁶ Tulane University School of Medicine, New Orleans, La.
⁷ BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Md. Electronic address: chris.ambrose@astrazeneca.com.

PMID: 38901615
DOI: 10.1016/j.jaip.2024.06.020

No abstract available

MeSH terms

Adult
Anti-Asthmatic Agents / therapeutic use
Asthma* / drug therapy
Asthma* / epidemiology
Asthma* / ethnology
Black or African American*
Female
Hispanic or Latino*
Humans
Male
Middle Aged
Severity of Illness Index
United States / epidemiology

Substances

Anti-Asthmatic Agents